MedPath
Found 453 clinical trials|View Analysis
Sort by:
Need a comprehensive medical report on "RNA"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals

A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

Not Applicable
Conditions
Hepatitis C, Chronic
Interventions
Behavioral: Incentive payment
First Posted Date
2020-06-11
Last Posted Date
2022-04-14
Lead Sponsor
Kirby Institute
Target Recruit Count
400
Registration Number
NCT04428346

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing

Recruiting
Conditions
Amyotrophic Lateral Sclerosis Type 4
Inherited Neurological Disorders of RNA Processing
First Posted Date
2020-05-20
Last Posted Date
2025-05-31
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
330
Registration Number
NCT04394871
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Phase 1
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2020-05-11
Last Posted Date
2025-03-20
Lead Sponsor
BioNTech SE
Target Recruit Count
75
Registration Number
NCT04382898
Locations
🇬🇧

Cancer Research UK Cambridge Centre, Cambridge, United Kingdom

🇬🇧

University of Glasgow, Beatson WoS Cancer Centre, Glasgow, United Kingdom

🇺🇸

University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 19 locations

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

Phase 1
Completed
Conditions
Virus Diseases
Infection Viral
RNA Virus Infections
Protection Against COVID-19 and Infections With SARS CoV 2
Infections, Respiratory
Vaccine Adverse Reaction
Interventions
Biological: BNT162c2
Biological: BNT162b2
Biological: BNT162b1
Biological: BNT162a1
First Posted Date
2020-05-08
Last Posted Date
2024-07-12
Lead Sponsor
BioNTech SE
Target Recruit Count
512
Registration Number
NCT04380701
Locations
🇩🇪

Universitäts Klinikum, Heidelberg, Germany

🇩🇪

Contract Research Organization, Mannheim, Germany

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

Phase 3
Recruiting
Conditions
COVID19
Coronavirus Infection
RNA Virus Infections
Coronavirus
Virus Diseases
Interventions
Other: Standard of Care
Biological: Convalescent Plasma 1 Unit
Biological: Convalescent Plasma 2 Units
First Posted Date
2020-05-06
Last Posted Date
2020-05-06
Lead Sponsor
West Virginia University
Target Recruit Count
240
Registration Number
NCT04376034
Locations
🇺🇸

WVU Medicine, Morgantown, West Virginia, United States

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Phase 2
Completed
Conditions
COVID-19
SARS-CoV-2 Infection
Interventions
Biological: BNT162b1
Biological: BNT162b2SA
Other: Placebo
Biological: BNT162b2
First Posted Date
2020-04-30
Last Posted Date
2023-02-28
Lead Sponsor
BioNTech SE
Target Recruit Count
47079
Registration Number
NCT04368728
Locations
🇺🇸

National Research Institute, Los Angeles, California, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

🇺🇸

Lynn Institute of Norman, Norman, Oklahoma, United States

and more 144 locations

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

Completed
Conditions
Asymptomatic Condition
Severe Acute Respiratory Syndrome Coronavirus 2
Coronaviridae Infections
Coronavirus Infections
RNA Virus Infections
Virus Diseases
Communicable Disease
Infection Viral
Interventions
Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2
First Posted Date
2020-04-29
Last Posted Date
2023-01-09
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
6313
Registration Number
NCT04367740
Locations
🇺🇸

Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Phase 1
Conditions
Coronaviridae Infections
Immunologic Disease
Antiviral Agents
Pneumonia
Virus Disease
Anti-infective Agents
Coronavirus Infection
Respiratory Tract Disease
Respiratory Tract Infections
RNA Virus Infections
Interventions
Biological: CYNK-001
First Posted Date
2020-04-28
Last Posted Date
2022-05-25
Lead Sponsor
Celularity Incorporated
Target Recruit Count
86
Registration Number
NCT04365101
Locations
🇺🇸

UC Irvine, Irvine, California, United States

🇺🇸

Multicare Health System, Tacoma, Washington, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study

Withdrawn
Conditions
COVID-19
First Posted Date
2020-04-24
Last Posted Date
2022-11-04
Lead Sponsor
University Medical Center Groningen
Registration Number
NCT04359459

The Role of Lipids in Immune Cell Function in SLE Patients

Conditions
Lupus Erythematosus, Systemic
Interventions
Other: Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
First Posted Date
2020-04-24
Last Posted Date
2020-04-24
Lead Sponsor
University College, London
Target Recruit Count
300
Registration Number
NCT04361734
Locations
🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy